Keyword Search
 
2017 | 2016 | 2015
Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study
April 18, 2017
Iclaprim met the primary endpoint   Iclaprim was well tolerated in the study   Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017   NDA submission expected in the first half of 2018 Company to host conference call today at 8:00 am EDT, 1:00 pm BST NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today ann... Read More
Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase
January 30, 2017
NEW YORK, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).    REVIVE-1 is a 600-patient double-blinded, global, multicenter trial... Read More
Appointment of Chief Financial Officer
January 17, 2017
NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announces that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies. Prior to joining Motif Bio, he was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage on... Read More